PDCD1 and melanoma: Most recent immunotherapy studies focus on antibodies to block the programmed cell death protein 1 (PD-1) or its ligands (e.g. PD-L1), which have enabled breakthroughs in the treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma [28–31].